ghadmin
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test.
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90%
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers, co-occurring mutations and molecular response to therapy
The Importance of Cancer Screening and Closing the “COVID-Induced Screening Gap”
In this post, we will discuss the basics of cancer screening, with a focus on general population screening, and work that has been implemented to improve screening rates.
Progress in Lung Cancer, Yet Barriers Remain
Lung cancer remains one of the most feared cancers, for good reason: Formerly diagnosed at a late stage with rapid progression to death, lung cancer has a legacy of pain, sadness and loss that has impacted so many families over decades.
Guardant Health Reports Third Quarter 2022 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2022.
Why This Message Motivates for Colorectal Cancer Screening
In the book Switch: How to Change Things When Change is Hard by the Heath brothers, the authors share a story about the St. Lucia Parrot that only exists on the island of St. Lucia.
Health Literacy and Colorectal Cancer Screening
“Medical jargon is killing us.” That’s according to Dr. Lisa Fitzpatrick. She is the founder of Grapevine Health, an organization providing trusted, data-driven, and relatable health information through trusted messengers. Dr. Fitzpatrick is on a mission to make health information less intimidating. She says that medical jargon is a thing of the past and health literacy is now en vogue – and can save patients’ lives.